Praxis Precision Medicines (PRAX) has announced encouraging topline results from its Phase 2, proof-of-concept study evaluating relutrigine in patients with SCN2A and SCN8A developmental and epileptic encephalopathy.
"When comparing to baseline rates, patients in the EMBOLD study experienced over 2,000 fewer seizures from the start of the trial. Achieving seizure freedom is the ultimate goal for these patients, and we were humbled by the progress made with relutrigine, as more than 30% of participants reached this significant milestone," stated Marcio Souza, President and CEO.
Following the announcement, shares of Praxis Precision Medicines saw a 5% increase in pre-market trading on Tuesday.
